This Week in Intellectual Property, October 22nd
News and Commentary In the Huffington Post, Daniel Maranas writes about the European Union's alternative "waiver" text in its negotiations over the TRIPS waiver. In it, he outlines the proposal [...]
A Conflicts of Law Approach to Intellectual Property Research
Intellectual property (IP) conflict of laws issues in disputes between private parties arise for a variety of reasons. Most infringe the plaintiff’s intellectual property rights in countries X, Y, and [...]
This Week in Intellectual Property, October 13th
News and Commentary The Niskanen Center has proudly joined a letter with a group of copyright reformers encouraging the Biden Administration to ensure that discussions of a TRIPS waiver--which the [...]
The AIA at Ten-How Much Do the Pre-AIA Prior Art Rules Still Matter?
As the America Invents Act (AIA) turns 10, patent students across the country may ask: if the law is already a decade old, why am I spending so much time [...]
This Week in Intellectual Property, October 8th
News and Commentary Writing for the Niskanen Center's main website, I discuss why the month of September has been so fantastic for drug pricing reform. After the Biden Administration's focus [...]
This Week in Intellectual Property, October 1st
News and Commentary In TechDirt, Mike Masnick criticizes an op-ed by Michael Rosen in The Hill. Rosen maintains that the proposed TRIPS waiver has done nothing to help the COVID-19 [...]
This Week in Intellectual Property, September 17th
Rent Check Happy Constitution Day! Last year I wrote a piece discussing the relationship between the Constitution, the Bill of Rights, and intellectual property rights. In summary, while intellectual property [...]
This Week in Intellectual Property, August 26th
News and Commentary Good news from the Tar Heel State: Judge Thomas Schroeder of the Middle District of North Carolina has declined a motion to dismiss a claim under the [...]
This Week in Intellectual Property, August 17th
News and Commentary Writing for The Washington Post, Professor Robin Feldman discusses how the oft-cited justification for the patent system as a way for drug companies to help compensate for [...]
Branded Price Variation in the United States Drug Market, 2010 to 2019
Branded drug prices command considerable attention in the United States yet defining a drug’s price is not straightforward because they vary substantially across settings. We link branded drug prices across [...]